Skip to main content

Hepatic Safety of Urate Lowering Therapies in Gout

Nov 27, 2018 4:42 pm

Lee and a group of Korean investigators have analyzed the comparative safety of allopurinol and febuxostat in a small cohort of gout patients with fatty liver disease (FLD) and found febuxostat had a lower risk for hepatotoxicity (defined as AST or ALT at least 3× the upper limit of normal) compared to allopurinol.

They identified 134 (relatively well matched) patients who had gout and FLD, 32 (23.9%) received febuxostat and 102 (76.1%) received allopurinol.

Hepatotoxicity was significantly lower in those on febuxostat (9.4%) compared to patients on allopurinol (35.3%, p = 0.005).

Comparatively, diabetes (HR 3.5) and colchicine use (HR 11.5) were associated a significantly higher risk of hepatotoxicity (p

 

Disclosures
The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×